MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
2269

2269.T

Meiji Holdings Co., Ltd.

$3786
36
 (0.96%)
Exchange:  JPX
Market Cap:  1.026T
Shares Outstanding:  278.778M
Delayed data
Calculate 2269.T Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Consumer Defensive
Industry:  Packaged Foods
   
CEO:  Katsunari Matsuda
Full Time Employees:  17270
Address: 
2-4-16, Kyobashi
Tokyo
104-0031
JP
Website:  https://www.meiji.com
Meiji Holdings Co., Ltd., established in Tokyo, Japan, in 1916, operates globally as a prominent manufacturer and seller across two core business segments: Food and Pharmaceutical. Its extensive Food division produces and markets a wide array of products, including various dairy items like yogurts, milk, cheeses, butter, and ice cream. This segment also encompasses a diverse selection of confectioneries, such as chocolates, gummy treats, and candies, alongside nutritional offerings like sports supplements, infant formulas, and beauty aids. Further contributions from the Food sector include frozen foods, sugar, over-the-counter medications, and livestock products, complemented by essential transportation and distribution services. The Pharmaceutical segment is dedicated to the development and provision of human health solutions, specifically targeting infectious diseases and central nervous system disorders, as well as manufacturing generic drugs, human and animal vaccines, and blood plasma products. Additionally, this division supplies a comprehensive range of veterinary medicines for livestock, fisheries, and companion animals, covering antimicrobials, pain relief, anti-inflammatory agents, and specialized treatments, alongside agricultural and livestock chemicals.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202420252026
Revenue1,105,494,0001,154,074,0001,173,688,000
Gross Profit327,345,000339,101,000359,040,000
EBITDA143,202,000137,842,000123,971,000
Operating Income84,322,00084,702,00093,307,000
Net Income50,675,00050,800,00035,077,000

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202420252026
Total Assets1,205,288,0001,184,472,0001,261,759,000
Total Liabilities417,492,000392,685,000444,204,000
Total Stockholders Equity746,532,000748,289,000772,587,000
Total Debt54,769,00052,127,000112,584,000
Cash and Cash Equivalents106,858,00078,191,00069,249,000

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202420252026
Operating Cash Flow107,983,00068,979,00056,522,000
Capital Expenditure-53,444,000-56,623,000-103,750,000
Free Cash Flow54,539,00012,356,000-47,228,000
Net Income50,675,00050,800,00035,077,000
Net Change in Cash41,894,000-36,435,0002,851,000

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2031Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)1,291,731,607.925Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)1,326,643,273.004Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)1,312,000,000Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)173,628,050.067Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)178,320,700.069Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)176,352,425.141Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)87,640,121.712Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)90,733,930.988Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)89,436,270.330Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)255,955,790.157Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)262,873,514.215Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)259,971,959.055Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)330Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)334.790Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)323.370Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)3Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)4Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
0.83
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
27.67
?Enterprise Value
 (TTM)
: 
1.014T  ?EV/FCF
 (TTM)
: 
-21.47
?Dividend Yield
 (TTM)
: 
0.03  ?Payout Ratio
 (TTM)
: 
0.79
?ROE
 (TTM)
: 
0.05  ?ROIC
 (TTM)
: 
0.05
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
0.15
?P/B
 (TTM)
: 
1.26  ?Current Ratio
 (TTM)
: 
1.87

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
3,688.05Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about 2269.T valuation

Is Meiji Holdings Co., Ltd. (2269.T) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Meiji Holdings Co., Ltd. (2269.T) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is 2269.T a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether 2269.T trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is 2269.T’s P/E ratio?

You can see 2269.T’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for 2269.T?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is 2269.T a good long-term investment?

Whether 2269.T fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

2269.T

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0.96
MARKETSnap

Trading Metrics:

Open: 3780   Previous Close: 3750
Day Low: 3750   Day High: 3807
Year Low: 2907   Year High: 4077
Price Avg 50: 3696.04   Price Avg 200: 3538.27
Volume: 861300   Average Volume: 1.046M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read